相关实验视频

Updated: Jul 9, 2025

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

在转换到延长释放的塔克罗利斯配方后,肝移植患者的胰岛素分泌

David Peretz^1,2, Nabiha Faisal^1,2, Julia Uhanova^1,2

¹Section of Hepatology.

Canadian liver journal

|November 29, 2023

概括

新型塔克罗利斯配方Envarsus-PA对肝移植患者的胰岛素分泌或葡萄糖水平没有显著影响. 这表明与其他类型的塔克罗利斯相比,它对移植后糖尿病风险具有类似的影响.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
内分泌学在内分泌学.
免疫学免疫学免疫学

背景情况:

肝移植后的糖尿病 (PLTDM) 影响了10-40%的接受者,增加了发病率和死亡率.
塔克罗利斯是一种常见的免疫抑制剂,可以以度依赖的方式抑制胰岛素分泌,从而导致PLTDM.

研究的目的:

评估Envarsus-PA,一种具有较低峰值度的新型塔克罗利斯配方,是否对胰岛素分泌有减少的抑制作用.
为了比较Envarsus-PA对葡萄糖平衡的影响与传统的塔克罗利斯配方.

主要方法:

在19名肝移植接受者中,使用恒温模式评估胰岛素分泌 (HOMA-S) 和c-水平评估胰岛素分泌.
测量是在转换到Envarsus-PA.之前和至少30天后进行的.
禁食血糖 (FBG) 和血红蛋白A1c (HbA1c) 水平也被监测.

主要成果:

转换为Envarsus-PA并没有显著改变HOMA-S或c-水平,表明胰岛素分泌没有变化.
禁食血糖和HbA1c水平在转化后保持稳定.
在葡萄糖恒温标志物中没有观察到统计学上显著的差异.

结论:

在成年肝移植接受者中,Envarsus-PA没有显著影响胰岛素分泌或葡萄糖平衡.
新配方在葡萄糖代谢方面似乎具有与其他塔克罗利斯配方相似的效果.
进一步的研究可能会探索长期结果和特定患者群体.

关键词:

这就是为什么PA PA PA PA.这就是Envarsussus的原因.配方配方配方是一个胰岛素的胰岛素胰岛素是什么这是一种分泌的分泌.这就是塔克罗利斯.

更多相关视频

Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice

Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice

Published on: October 31, 2007

Intraportal Transplantation of Pancreatic Islets in Mouse Model

Intraportal Transplantation of Pancreatic Islets in Mouse Model

Published on: May 5, 2018

相关概念视频

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...